Rifaximin in Patients With Gastroesophageal Variceal Bleeding

• Status: Completed
• Trial end date: 2018-02-28
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to evaluate the safety and efficacy of Rifaximin in the treatment of cirrhotic gastroesophageal variceal bleeding.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Zhongshan Hospital
• Treatments: Rifamycins; Rifaximin

Criteria

Inclusion Criteria:

• 18 y.o. ≤age≤75 y.o.;

• Cirrhotic gastroesophageal variceal bleeding underwent endoscopic treatment (include esophageal varices ligation, endoscopic injection sclerosis and gastric N- butyl-cyanoacrylate injection).

Exclusion Criteria:

• age <18 y.o. or age > 75 y.o.;

• Never had the variceal bleeding episode before;

• Do not have endoscopic treatment;

• Combined with other malignant tumors (not exclude patients with hepatocellular carcinoma who don't need treatment at the moment);

• Known infection after endoscopic treatment (Fever, microbial cultures positive, et al.)

• Massive ascites or combined with other high-risk factors that require prophylaxis use of antibiotics.

• Acute variceal bleeding within 5 days.

• Refuse to participate